Who Benefits Most from Morphokinetic Cellular Analysis?

Andrew Chasteen from Accelerate Diagnostics, Inc, discusses who will benefit most from Morphokinetic Cellular Analysis (MCA) keeping in mind the challenges posed by antibiotic resistance.

Interview Transcript (slightly modified for readability)

“The ultimate beneficiary of MCA is the patient. [Patients] benefit primarily by having a very optimized approach to their antibiotic regimen. In many cases we hear, especially lately, about antibiotic resistance and the challenges that that poses, certainly for the patient, but also for the clinician. [Clinicians are] in a situation where they have to use the best information that they have in order to optimize and provide the best care as possible. But the reality is, is that they don’t have what they really need, fast enough.”